Skip to content

Prevalence of vascular pathology associated with self-reported symptoms of digital ischemia in (a)symptomatic elite male volleyball players in the Netherlands

Prevalence of vascular pathology associated with self-reported symptoms of digital ischemia in (a)symptomatic elite male volleyball players in the Netherlands - Prevalence of vascular pathology in elite male volleyball players

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON38927
Enrollment
130
Registered
2013-11-13
Start date
2013-11-25
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arterial disease of the shoulder PCHA aneurysm

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Players with symptoms associated digital ischemia: - Male volleyball players active in the Dutch national top league in the seasons 2012-2013 and/or 2013-2014. - Players who report to *sometimes or more often suffer from cold or blue or pale digits in the dominant hand during or directly after practice or competition*. - Written informed consent.;Players without symptoms associated with digital ischemia: - Male volleyball players active in the Dutch national top league in the seasons 2012-2013 and/or 2013-2014. - Players who do not report to *sometimes or more often suffer from cold or blue or pale digits in the dominant hand during or directly after practice or competition*. - Written informed consent.

Exclusion criteria

Exclusion criteria: - A history of vascular surgery to the dominant shoulder. - A history of vascular disease - Age

Design outcomes

Primary

MeasureTime frame
Prevalence of PCHA anomalies in symptomatic and asymptomatic elite male volleyball players.

Secondary

MeasureTime frame
NVT

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)